Cytokine network in psoriasis revisited

European Cytokine Network

Volumn 22, Issue 4, 2011, Pages 160-168

  Michalak Stoma, Anna ^a   Pietrzak, Aldona ^a   Szepietowski, Jacek C ^b   Zalewska Janowska, Anna ^c   Paszkowski, Tomasz ^a   Chodorowska, Grazyna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cytokine; Interleukin; Psoriasis; Th1; Th17; Th2

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 2; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 26; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CELLULAR IMMUNITY; CYTOKINE PRODUCTION; HELPER CELL; HISTOPATHOLOGY; HUMAN; NONHUMAN; PATHOGENESIS; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; SKIN DEFECT; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; TH22 CELL;

CYTOKINES; HUMANS; PSORIASIS; SKIN; TH1 CELLS; TH17 CELLS;

EID: 84857002192     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2011.0294     Document Type: Review

References (136)

1. Hueber AJ, McInnes IB. Immune regulation in psoriasis and psori-atic arthritis-recent developments. Immunol Lett 2007; 114: 59-65.
2. Prinz JC. From benchtobedside-translational researchinpsoriasis. JEADV 2010; 24: 1-4.
3. Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493-1499.
4. Mak RKH, Hundhausen C, Nestle FO. Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr 2009; 100: 2-13.
5. Kagami S, Rizzo HL, Lee JJ et al. Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis. J Invest Dermatol 2010; 130: 1373-1383.
6. Duhen T, Geiger R, Jarrossay D et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009; 10: 857-863.
7. Liu Y, Yang B, Zhou M et al. Memory IL-22-producing CD4(+) T cells specific for Candida albicans are present in humans. Eur J Immunol 2009; 39: 1472-1479.
8. Trifari S, Kaplan CD, Tran EH, et-al. Identificationofahuman helper T cell population that has abundant productionof interleukin22 and is distinct fromT(H)-17, T(H)1 and T(H)2 cells.Nat Immunol2009; 10: 864-871.
9. Boniface K, Blom B, Liu YJ, de Waal Malefyt R. From interleukin-23toT-helper17cells: human T-helper cell differentiation revisited. Immunol Rev 2008; 226: 132-146.
10. Di Cesare A, Di Meglio P and Nestle FO. The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis. J Invest Dermatol 2009; 129: 1339-1350.
11. Chen Z, O'Shea JJ. Regulation of IL-17 production in human lymphocytes. Cytokine 2008; 41: 71-78.
12. Asarch A, Barak O, Loo DS, Gottlieb AB. Th17 cells: A new therapeutic targetininflammatory dermatoses.J Dermatolog Treat2008; 19: 318-326.
13. Baran W, Szepietowski JC, Mazur G, Baran E. TGF-beta(1) gene polymorphism in psoriasis vulgaris. Cytokine 2007; 38: 8-11.
14. Nockowski P, Szepietowski JC, Ziarkiewicz M, Baran E. Serum concentrations of transforming growth factor beta 1 in patients with psoriasis vulgaris. Acta Dermatovenerol Croat 2004; 12: 2-6.
15. McGeachy MJ, Cua DJ. T cells doing it for themselves: TGFbeta regulation of Th1 and Th17 cells. Immunity 2007; 26: 547-549.
16. Asarch A, Barak O, Loo DS, Gottlieb AB. Th17 cells: A new paradigm for cutaneous inflammation. J Dermatolog Treat 2008; 19: 259-266.
17. Grossman RM, Krueger J, Yourish D et al. Interleukin6isexpressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A 1989; 86: 6367-6371.
18. Miranda-Carus ME, Benito-Miguel M, Llamas MA et al. Human T cellsconstitutively express IL-15 that promotesexvivoTcell home-ostatic proliferation through autocrine/juxtacrine loops. J Immunol 2005; 175: 3656-3662.
19. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008; 223: 87-113.
20. McInnes IB, Gracie JA. Interleukin-15: A new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004; 4: 392-397.
21. Villadsen LS, Schuurman J, Beurskens F et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003; 112: 1571-1580.
22. Zhang N, Pan HF, Ye DQ. Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Mol Cell Biochem 2011; 353: 41-46.
23. Pietrzak A, Zalewska A, Chodorowska G et al. Genes and structure of selected cytokines involved in pathogenesis of psoriasis. Folia Histochem Cytobiol 2008; 46: 11-21.
24. Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol 1993; 11: 245-267.
25. Pietrzak AT, Zalewska A, Chodorowska G et al. Cytokines and anticytokines in psoriasis. Clin ChimActa 2008; 394: 7-21.
26. Reich A, Szepietowski JC. Mediators of Pruritus in Psoriasis. Mediators Inflamm 2007; 2007:64727.
27. Nakamura M, Toyoda M, Morohashi M. Pruritogenicmediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol 2003; 149: 718-730.
28. Franchi C, Cainelli G et al. Association of cyclosporine and 311 nM UVB in the treatment of moderate to severe forms of psoriasis: a new strategic approach. Int JImmunopathol Pharmacol 2004; 17: 401-406.
29. Nograles KE, Davidovici B, Krueger JG. New insights in the Immunologic Basis of Psoriasis. Semin Cutan Med Surg 2010; 29: 3-9.
30. Kryczek I, Bruce AT, Gudjonsson JE, et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 2008; 181: 4733-4741.
31. Harper EG, Guo CH, Rizzo H et al. Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis. J Invest Dermatol 2009; 129: 2175-2183.
32. Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. JExpMed2007; 204:1849-61.
33. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-957.
34. Little MC, Gawkrodger DJ, Mac Neil S. Differentiation of human keratinocytes is associated with a progressive loss of interferon--y-induced intercellular adhesion molecule 1 expression. Br J Dermatol 1996; 135: 24-31.
35. Szegedi A, Aleksza M, Gonda A et al. Elevated rate of Thelper1 (TH1) lymphocytes and serum IFN--y levels in psoriatic patients. Immunol Lett 2003; 86: 277-280.
36. Abdel-Hamid MF, Aly DG, Saad NE et al. Serum levels of interleukin-8, tumor necrosis factor-a and -y-interferon in Egyptian psoriatic patients and correlation with disease severity. J Dermatol 2011; 38: 442-446.
37. Chodorowska G. Plasma concentrations of IFN--y and TNF-a in psoriatic patients before and after local treatment with dithranol ointment. J Eur Acad Dermatol Venereol 1998; 10: 147-151.
38. Austin LM, Ozawa M, Kikuchi T et al. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 113: 752-759.
39. Zhou X, Krueger JG, Kao MC et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003; 13: 69-78.
40. Uyemura K, Yamamura M, Fivenson DF et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helpertype 1 cell-mediated response. J Invest Dermatol 1993; 101: 701-705.
41. Barna M, Snijdewint FGM, Van der Heijden FL et al. Characterization of lesional psoriatic skin T lymphocyte clones. Acta Derm Venereol Suppl (Stockh) 1994; 186: 9-11.
42. Ravic-Nikolic A, Radosavljevic G, Jovanovic I et al. Systemic pho-tochemotherapy decreases the expression of IFN--y, IL-12p40 and IL-23p19 in psoriatic plaques. Eur J Dermatol 2011; 21: 53-57.
43. Goetz FW, Planas JV, MacKenzie S. Tumor necrosis factor. Dev Comp Immunol 2004; 28: 487-495.
44. Schottelius AJG, Moldawer LL, Dinarello CA et al. Biology of tumor necrosis factor-a - implications for psoriasis. Exp Dermatol 2004; 13: 193-222.
45. Ware CF. The TNF superf amily. Cytokine Growth Factor Rev 2003; 14: 181-184.
46. Makhatadze NJ. Tumor necrosis factor locus: genetic organisation and biological implications. Human Immunol 1998; 59: 571-579.
47. Aggarwal BB, Natarajan K. Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw 1996; 7: 93-124.
48. Groves RW, Allen MH, Ross EL et al. Tumor necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br J Dermatol 1995; 132: 345-352.
49. Zaba LC, Cardinale I, Gilleaudeau P et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007; 204: 3183-3194.
50. Gottlieb AB, Chamian F, Masud S et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005; 175: 2721-2729.
51. Iwamoto S, Iwai S, Tsujiyama K et al. TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. J Immunol 2007; 179: 1449-1457.
52. Bonifati C, Carducci M, Cordiali Fei P et al. Correlated increases of tumour necrosis factor-a, interleukin-6 and granulocyte monocyte - colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationship with disease severity. Clin Exp Dermatol 1994; 19: 383-387.
53. Ettehadi P, Greaves MW, Wallach D et al. Elevated tumour necrosis factor-alpha (TNF) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-151.
54. Kristensen M, Chu CQ, Eedy DJ et al. Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 1993; 94: 354-362.
55. Mussi A, Bonifati C, Carducci M et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997; 11: 115-118.
56. Mizutani H, Ohmoto Y, Mizutani T et al. Role of increased production of monocytes TNF-a, IL-1 fj and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 1997; 14: 145-153.
57. Ettehadi P, Greaves MW, Wallach D et al. Elevated tumour necrosis factor-alpha (TNF) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-151.
58. Olaniran AK, Baker BS, Paige DG et al. Cytokine expression in psoriatic skin lesions during PUVA therapy. Arch Dermatol Res 1996; 288: 421-425.
59. Tigalonova M, Bjerke JR, Gallati H et al. Serum levels of interferons and TNF-a are not correlated to psoriasis activity and therapy. Acta Derm Venereol 1994; 186: 25-27.
60. Menter A. Recent advances in Psoriasis Therapy and the Work of the International Psoriasis Council. US Derm Review 2006; 1: 23-27.
61. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25: 821-852.
62. Yao Z et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995; 155: 5483-5486.
63. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes and Infection 2009; 11: 625-630.
64. Shin HC, Benbernou N, Esnault S, Guenounou M. Expression of IL-17 in human memory CD45RO+ T lymphocytes and its regulation by protein kinase A pathway. Cytokine 1999; 11: 257-266.
65. Roark CL, Simonian PL, Fontenot AP et al. Gammadelta T cells: an important source of IL-17. Curr Opin Immunol 2008; 20: 353-357.
66. Blauvelt A. T-Helper 17 Cells in Psoriatic Plaques and Additional Genetic Links between IL-23 and Psoriasis. J Invest Dermatol 2008; 128: 1064-1067.
67. Lockhart E, Green AM, Flynn JL. IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 2006; 177: 4662-4669.
68. Coury F, Annels N, Rivollier A et al. Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med 2008; 4: 81-87.
69. Michel ML, Keller AC, Paget C et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 2007; 204: 995-1001.
70. Rachitskaya AV, Hansen AM, Horai R et al. Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol 2008; 180: 5167-5171.
71. Armstrong AW, Voyles SV, Armstrong EJ et al. Rutledge. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol 2011; 20: 544-549.
72. Acosta-Rodriguez EV, Rivino L, Geginat J et al. Surface pheno-type and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007; 8: 639-646.
73. Matsushita S, Higashi T. Human Th17 Cell Clones and Natural Immune Responses. Allergol Int 2008; 57: 135-140.
74. Hirota K, Yoshitomi H, Hashimoto M et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its Animals model. J Exp Med 2007; 204: 2803-2812.
75. Aujla SJ, Dubin PJ, Kolls JK. Th17 cells and mucosal host defense. Semin Immunol 2007; 19: 377-382.
76. Zelante T et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007; 37: 2695-2706.
77. Lowes MA, Kikuchi T, Fuentes-Duculan J et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T Cells. J Invest Dermatol 2008; 128: 1207-1211.
78. Wolk K, Witte E, Wallace E et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006; 36: 1309-1323.
79. Cosmi L, De Palma R, Santarlasci V et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 2008; 205: 1903-1916.
80. Liang SC et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-2279.
81. Cella X et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009; 457:722-725.
82. Duhen T, Geiger R, Jarrossay D et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009; 10: 857-863.
83. Liu Y, Yang B, Zhou M et al. Memory IL-22-producing CD4(+) T cells specific for Candida albicans are present in humans. Eur J Immunol 2009; 39: 1472-1479.
84. Sabat R, Wolk K. Research in practice: IL-22 and IL-20: significance for epithelial homeostasis and psoriasis pathogenesis.J Dtsch Dermatol Ges 2011; doi: 10.1111/j.1610-0387.2011.07611.x.
85. Wolk K, Sabat R. Interleukin-22: a novel T and NK cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 2006; 17: 367-380.
86. Aujla SJ, Kolls JK. IL-22: A critical mediator in mucosal host defense. J Mol Med 2009; 87: 451-454.
87. Boniface X et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005; 174: 3695-3702.
88. Zheng X et al. Interleukin 22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008; 14: 282-289.
89. Andoh X et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responsesincolonic subepithelialmyofibrob-lasts. Gastroenterol 2005; 129: 969-984.
90. Boniface K, Guignouard E, Pedretti N, et al. Arole forT cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007; 150: 407-415.
91. Caproni M, Antiga E, Melani L et al. Serum levels of IL-17 and IL-22 are reduced by Etanercept, but not by Acitretin, in patients with psoriasis: a randomized controlled trial. J Clin Immunol 2009; 29: 210-214.
92. Gutowska-Owsiak D, Schaupp AL, Salimi M et al. Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes. Br J Dermatol 2011; 165: 492-498.
93. Tokura Y, Mori T, Hino R. Psoriasis and other Th17-mediated skin diseases. J UOEH 2010; 32: 317-328.
94. Eyerich S, Eyerich K, Pennino D et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009; 119: 3573-3585.
95. Tohyama M, Hanakawa Y, Shirakata Y et al. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol 2009; 39: 2779-2788.
96. Donnelly RP, Sheikh F, Dickensheets H et al. Interleukin-26: An IL-10-related cytokine produced by Th17 cells. Cytokine Growth Factor Rev 2010; 21: 393-401.
97. Ouyang W, Rutz S, Crellin NK et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011; 29: 71-109.
98. Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-725.
99. Duvallet E, Semerano L, Assier E et al. Interleukin-23: A key cytokine in inflammatory diseases. Ann Med 2011; doi: 10.3109/07853890.2011.577093.
100. Wendling D. Interleukin 23:akey cytokinein chronic inflammatory disease. Joint Bone Spine 2008; 75: 517-9.
101. Fitch E, Harper E, Skorcheva I, et al. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007; 9: 461-467.
102. Parham C et al. A receptor for the hetero- dimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002; 168: 5699-5708.
103. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007; 25: 221-242.
104. Capon F, Di Meglio P, Szaub J et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007; 122: 201-206.
105. Cargill M, Schrodi SJ, Chang M et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80: 273-290.
106. D'Elios MM, Del Prete G, Amedei A. Targeting IL-23 in human diseases. Expert Opin Ther Targets 2010; 14: 759-774.
107. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006; 27: 17-23.
108. Harrington LE, Hatton RD, Mangan PR et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from theThelper type1and2lineages.Nat Immunol 2005;6:1123-1132.
109. Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.
110. Dubin PJ, Kolls JK. Th17 cytokines and mucosal immunity. Immunol Rev 2008; 226: 160-171.
111. Tonel G, Conrad C, Laggner U et al. Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis. J Immunol 2010; 185: 5688-569.
112. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006; 176: 1908-1915.
113. Chan JR, Blumenschein W, Murphy E et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006; 203: 2577-2587.
114. Lee E, Trepicchio WL, Oestreicher JL, etal. Increased expression of interleukin 23 p19 and p40 in lesional skinof patients with psoriasis vulgaris. J Exp Med 2004; 199: 125-130.
115. Duffin KC, Woodcock J, Krueger GG. Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. Dermatol Ther 2010; 23: 101-111.
116. Di Meglio P, Nestle FO. The role of IL-23 in the immunopathogen-esis of psoriasis. F1000 Biol Rep 2010; 2: 40.
117. Zheng Y et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-651.
118. Toichi E et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006; 177: 4917-4926.
119. Wolk K, Witte E, Warszawska K et al. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: anovel immuno- logical cascade with potential relevance in psoriasis. Eur J Immunol 2009; 39: 3570-3581.
120. Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 2002; 168: 5397-5402.
121. Wolk K, Witte K, Witte E et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 2008; 83: 1181-1193.
122. Kunz S, Wolk K, Witte E et al. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are di- stinct from classical ILs. Exp Dermatol 2006; 15: 991-1004.
123. Sabat R, Wallace E, Endesfelder S, Wolk K. IL-19 and IL-20: two novel cytokines with importance in inflam- matory diseases. Expert Opin Ther Targets 2007; 11: 601-612.
124. Wolk K, Haugen HS, Xu W et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009; 87: 523-536.
125. Berard M, Brandt K, Bulfone-Paus S, Tough DF. IL-15 promotes the survival of naïve and memory phenotype CD8+ T cells. J Immunol 2003; 170: 5018-5026.
126. Waldmann TA. IL-15 in the life and death of lymphocytes: immunotherapeutic implications. Trends Mol Med 2003; 9: 517-521.
127. Elder JT. IL-15 and psoriasis: another genetic link to Th17? J Invest Dermatol 2007; 127: 2495-2497.
128. Rückert R, Asadullah K, Seifert M et al. Inhibition of keratinocyte apoptosis by IL- 15: a new parameter in the pathogenesis of psoriasis. J Immunol 2000; 165: 2240-2250.
129. Danning CL, Illei GG, Hitchon C et al. Macrophage-derived cytokine and nuclear factorkBp65 expressionn synovial membrane and skinof patients with psoriatic arthritis. Arthritis Rheumat 2000; 43: 1244-1256.
130. Kane D, Gogarty M, O'Leary J et al. Reduction of synovial sublin-ing layer inflammation and proinflamma- tory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheumat 2004; 50: 3286-3295.
131. Yano S, Komine M, Fujimoto M et al. Interleukin 15 induces the signals of epiderma proliferation through ERK and PI 3-kinase In a human epiderma keratinocyte cell line, HaCaT. Biochem Biophys Res Commun 2003; 301: 841-847.
132. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001; 97: 14-32.
133. McInnes IB, Gracie JA. Interleukin-15:anew cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004; 4: 392-397.
134. Villadsen LS, Schuurman J, Beurskens F et al. Resolution of psoriasis upon blockade of IL- 15 biological activity in a xenograft mouse model. J Clin Invest 2003; 112:1571-1580.
135. Yan KL, Huang W, Zhang XJ et al. Follow-up analysis of PSORS9 in 151 Chinese families confirmed the linkage to 4q31-32 and refined the evidence to the families of early-onset psoriasis. J Invest Dermatol 2007; 127: 312-318.
136. Zhang XJ, Yan KL, Wang ZM et al. Polymorphisms in interleukin-15 gene on chromosome 4q31.2 are associated with psoriasis vulgaris in Chinese population. J Invest Dermatol 2007; 127: 2544-2551.